ABHD6 and metabolic syndrome: Recent studies suggest that ABHD6 inhibitor have promising therapeutic efficacy in several preclinical mouse models of devastating diseases (Cao et al., 2019), such as metabolic syndrome (Thomas et al., 2013), chronic inflammation (Alhouayek et al., 2013), diabetes (Zhao et al., 2014), including traumatic brain injury (Tchantchou and Zhang, 2013), multiple sclerosis (Manterola et al., 2018), and epilepsy (Naydenov et al., 2014).